Immupharma (IMM)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

3.01p
   
  • Change Today:
    -0.095p
  • 52 Week High: 6.94
  • 52 Week Low: 1.59
  • Currency: UK Pounds
  • Shares Issued: 333.40m
  • Volume: 280,236
  • Market Cap: £10.04m
  • RiskGrade: 328

Deal with Barclays    Trade now with Barclays Stockbrokers

Growth Ratings

EPS Growth shows the relative growth of a company's earnings over the last year.

The rise in total monies receivable for goods / services sold before expenses.

1yr EPS Growth Not Available
1yr Revenue Growth Not Available

Income Ratings

The percentage of the share price that a company pays out as dividends over a year.

The percentage change from the previous year in the dividend paid on each share.

Dividend Yield Not Available
1yr DPS Growth Not Available

Valuation Ratings

The share price as a ratio of revenue per share.

The share price as a ratio of net asset value.

Price Sales Ratio Not Available
Price Book Ratio
72.97% below the market average72.97% below the market average72.97% below the market average72.97% below the market average72.97% below the market average
41.38% below the sector average41.38% below the sector average41.38% below the sector average41.38% below the sector average41.38% below the sector average

Performance Ratings

In percentage total change in share price over 30 days.

In percentage total change in share price over 3 months.

Price Chg 30d
38.95% above the market average38.95% above the market average38.95% above the market average38.95% above the market average38.95% above the market average
47.54% above the sector average47.54% above the sector average47.54% above the sector average47.54% above the sector average47.54% above the sector average
Price Chg 3m
92.14% above the market average92.14% above the market average92.14% above the market average92.14% above the market average92.14% above the market average
80.33% above the sector average80.33% above the sector average80.33% above the sector average80.33% above the sector average80.33% above the sector average

Technical Ratings

The Relative Strength Index measures a share price relative to itself and its recent history.

Momentum is an oscillator that measures the rate of price change.

RSI
33.66% above the market average33.66% above the market average33.66% above the market average33.66% above the market average33.66% above the market average
48.28% above the sector average48.28% above the sector average48.28% above the sector average48.28% above the sector average48.28% above the sector average
Momentum 20
32.80% above the market average32.80% above the market average32.80% above the market average32.80% above the market average32.80% above the market average
44.83% above the sector average44.83% above the sector average44.83% above the sector average44.83% above the sector average44.83% above the sector average

Management Ratings

Operating Margin is profit as a percentage of sales.

Return on capital employed measures the return from invested and borrowed capital.

Operating Margin Not Available
ROCE Not Available

Profitability Ratings

Earnings per share, the company's profitability expressed on a per share basis.

Analysts' estimates of future EPS for the next 2 years.

EPS
54.91% below the market average54.91% below the market average54.91% below the market average54.91% below the market average54.91% below the market average
6.67% below the sector average6.67% below the sector average6.67% below the sector average6.67% below the sector average6.67% below the sector average
Forecast EPS Not Available

Profit/Loss Ratings

Monies produced from sales of goods and services after trade discounts, VAT, etc.

Operating Profit is the profit after deducting operating costs from gross profits.

Turnover Not Available
Operating Profit Loss
62.62% below the market average62.62% below the market average62.62% below the market average62.62% below the market average62.62% below the market average
6.67% above the sector average6.67% above the sector average6.67% above the sector average6.67% above the sector average6.67% above the sector average

Balance Sheet Ratings

The difference between current assets and current liabilities.

A current asset representing the company's financial liquidity.

Assets
74.9% below the market average74.9% below the market average74.9% below the market average74.9% below the market average74.9% below the market average
82.46% below the sector average82.46% below the sector average82.46% below the sector average82.46% below the sector average82.46% below the sector average
Cash
75.43% below the market average75.43% below the market average75.43% below the market average75.43% below the market average75.43% below the market average
86.67% below the sector average86.67% below the sector average86.67% below the sector average86.67% below the sector average86.67% below the sector average

Director Deal Ratings

The cumulative amount of stocks sold by company directors over 1 year

The cumulative amount of stocks bought by company directors over 1 year

Sells 1y Not Available
Buys 1y
13.13% above the market average13.13% above the market average13.13% above the market average13.13% above the market average13.13% above the market average
25.71% above the sector average25.71% above the sector average25.71% above the sector average25.71% above the sector average25.71% above the sector average

Broker Ratings

The percentage of stockbrokers that rate the company as a Buy

The percentage of stockbrokers that rate the company as a Hold

Brokers Percent Buy Not Available
Brokers Percent Neutral Not Available

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Immupharma Market Data

Currency UK Pounds
Share Price 3.01p
Change Today -0.095p
% Change -3.06 %
52 Week High 6.94
52 Week Low 1.59
Volume 280,236
Shares Issued 333.40m
Market Cap £10.04m
RiskGrade 328

Immupharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
57.49% below the market average57.49% below the market average57.49% below the market average57.49% below the market average57.49% below the market average
16.67% below the sector average16.67% below the sector average16.67% below the sector average16.67% below the sector average16.67% below the sector average
Price Trend
30.73% below the market average30.73% below the market average30.73% below the market average30.73% below the market average30.73% below the market average
14.75% below the sector average14.75% below the sector average14.75% below the sector average14.75% below the sector average14.75% below the sector average
Income Not Available
Growth Not Available

Immupharma Dividends

No dividends found

Trades for 26-May-2023

Time Volume / Share Price
16:09 31,840 @ 2.94p
15:38 199 @ 3.00p
14:19 4,000 @ 2.94p
14:13 100,000 @ 3.00p
14:10 49,646 @ 3.01p

Immupharma Key Personnel

CEO Dimitri Dimitriou

Top of Page